Product Description
Ahn-Gook was developing agsav-301, an oral L-Type Calcium Channel Blocker and ARB Blocker, for the treatment of patients with hypertension (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01536353)
Mechanisms of Action: L-Type Calcium Channel Blocker,ARB Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ahn-Gook
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 1110-AGSAV-P1 | P1 |
Completed |
Hypertension |
2012-04-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|